Phase 2 Immunodeficiency Clinical Trials
23 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 23 trials
Recruiting
Phase 1Phase 2
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting
Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting
Phase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2Phase 3
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled47 locationsNCT07266831
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Assistance Publique - Hôpitaux de Paris7 enrolled1 locationNCT05071222
Recruiting
Phase 2
Baricitinib for Reduction of HIV - CNS
Human Immunodeficiency Virus
William Tyor95 enrolled2 locationsNCT05452564
Recruiting
Phase 2
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
COVID-19Immunodeficiency
ANRS, Emerging Infectious Diseases256 enrolled18 locationsNCT05587894
Recruiting
Phase 2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Immune DysregulationPrimary Immune Regulatory DisorderCommon Variable Immunodeficiency (CVID)+4 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 2
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
COVID-19Immunodeficiency
Calmy Alexandra256 enrolled4 locationsNCT07406217
Recruiting
Phase 1Phase 2
Autologous Gene Therapy for Artemis-Deficient SCID
Severe Combined Immunodeficiency
University of California, San Francisco24 enrolled1 locationNCT03538899
Recruiting
Phase 2
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Juvenile Rheumatoid Arthritis (JRA)Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes+4 more
Paul Szabolcs100 enrolled1 locationNCT01962415
Recruiting
Phase 2
Reducing Systemic Inflammation in People on Antiretroviral Therapy
Cardiovascular Risk FactorHuman Immunodeficiency Virus (HIV)
Centre hospitalier de l'Université de Montréal (CHUM)150 enrolled1 locationNCT07030920
Recruiting
Phase 2
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Phase 2
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Interstitial Lung DiseaseCommon Variable Immunodeficiency
Children's Hospital Medical Center, Cincinnati38 enrolled6 locationsNCT04925375
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)66 enrolled1 locationNCT04339777
Recruiting
Phase 1Phase 2
Phase Ib/IIa Clinical Study of ACC017 Tablets
Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.36 enrolled1 locationNCT06719310
Completed
Phase 2
An open-label study of the safety and efficacy of 12 weeks treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) with only partial immune reconstitution.
Human Immunodeficiency Virus-1 infection
Biotron Limited20 enrolled3 locationsACTRN12621001354875